# Mentari Therapeutics

> Biotech developing anti-PACAP and anti-CGRP bispecific antibodies for migraine prevention.

## Why it is interesting

Paragon spinout targeting complementary migraine pathways — a16z Bio + Health among backers in a $290M private placement ahead of a reverse merger with InMed (2026).

## Profile

- **Stage:** growth
- **Status:** private
- **Industries:** biotech-life-sciences, healthtech
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Private placement (2026): ~$290M led by Fairmount; a16z Bio + Health among participants ahead of InMed merger (BioPharma Dive)
- Follow-on placement (Jul 2026): $200M from Fairmount, Venrock Healthcare, Blackstone Multi-Asset, and others (SEC filing)
- Co-investors: no additional institutional investors disclosed in public sources reviewed 2026-07-24

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/mentari-therapeutics